FR2460676A1 - Vaccin contre la rhinotracheite bovine infectieuse - Google Patents

Vaccin contre la rhinotracheite bovine infectieuse Download PDF

Info

Publication number: FR2460676A1
Authority: FR; France
Prior art keywords: virus; ibr; protein; vaccine; aqueous solution
Prior art date: 1979-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

FR8014845A

Other languages

English (en)

French (fr)

Inventor

Harold Wayne Lupton

David Ellsworth Reed

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Iowa State University Research Foundation Inc ISURF

Original Assignee

Iowa State University Research Foundation Inc ISURF

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-07-09

Filing date

1980-07-03

Publication date

1981-01-30

1980-07-03 Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF

1981-01-30 Publication of FR2460676A1 publication Critical patent/FR2460676A1/fr

Status Withdrawn legal-status Critical Current

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 90
208000005562 infectious bovine rhinotracheitis Diseases 0.000 title abstract description 46
241000700605 Viruses Species 0.000 claims abstract description 60
102000004169 proteins and genes Human genes 0.000 claims abstract description 28
108090000623 proteins and genes Proteins 0.000 claims abstract description 28
239000002671 adjuvant Substances 0.000 claims abstract description 23
239000003599 detergent Substances 0.000 claims abstract description 18
108010003533 Viral Envelope Proteins Proteins 0.000 claims abstract description 13
210000004779 membrane envelope Anatomy 0.000 claims abstract description 7
230000003053 immunization Effects 0.000 claims abstract description 5
238000002649 immunization Methods 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 35
241000283690 Bos taurus Species 0.000 claims description 22
208000015181 infectious disease Diseases 0.000 claims description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 14
239000007864 aqueous solution Substances 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
230000003612 virological effect Effects 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 6
238000012546 transfer Methods 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
210000000170 cell membrane Anatomy 0.000 claims description 3
230000001737 promoting effect Effects 0.000 claims description 3
239000006185 dispersion Substances 0.000 claims description 2
230000001902 propagating effect Effects 0.000 claims description 2
230000002458 infectious effect Effects 0.000 claims 3
102000002067 Protein Subunits Human genes 0.000 claims 1
108010001267 Protein Subunits Proteins 0.000 claims 1
206010051497 Rhinotracheitis Diseases 0.000 claims 1
230000009851 immunogenic response Effects 0.000 claims 1
208000019423 liver disease Diseases 0.000 claims 1
241001465754 Metazoa Species 0.000 abstract description 12
238000000605 extraction Methods 0.000 abstract description 6
238000002255 vaccination Methods 0.000 description 30
244000309466 calf Species 0.000 description 22
239000002609 medium Substances 0.000 description 20
241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 16
229920004890 Triton X-100 Polymers 0.000 description 15
239000013504 Triton X-100 Substances 0.000 description 15
210000002966 serum Anatomy 0.000 description 14
239000002054 inoculum Substances 0.000 description 12
BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 11
108091003079 Bovine Serum Albumin Proteins 0.000 description 10
239000000284 extract Substances 0.000 description 10
238000006386 neutralization reaction Methods 0.000 description 10
239000012894 fetal calf serum Substances 0.000 description 9
230000028327 secretion Effects 0.000 description 9
239000000243 solution Substances 0.000 description 8
238000011081 inoculation Methods 0.000 description 7
238000007918 intramuscular administration Methods 0.000 description 7
230000000890 antigenic effect Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
239000008272 agar Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000010410 layer Substances 0.000 description 5
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
206010000210 abortion Diseases 0.000 description 4
231100000176 abortion Toxicity 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
244000144972 livestock Species 0.000 description 3
210000005265 lung cell Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012770 revaccination Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
239000010414 supernatant solution Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
208000032420 Latent Infection Diseases 0.000 description 2
241000609499 Palicourea Species 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
229960002064 kanamycin sulfate Drugs 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
229960002385 streptomycin sulfate Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010004078 Balanoposthitis Diseases 0.000 description 1
241000030939 Bubalus bubalis Species 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
206010044302 Tracheitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
201000011475 meningoencephalitis Diseases 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
229960003127 rabies vaccine Drugs 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000005185 salting out Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000002381 testicular Effects 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000014599 transmission of virus Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
208000010484 vulvovaginitis Diseases 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

FR8014845A 1979-07-09 1980-07-03 Vaccin contre la rhinotracheite bovine infectieuse Withdrawn FR2460676A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5582179A	1979-07-09	1979-07-09

Publications (1)

Publication Number	Publication Date
FR2460676A1 true FR2460676A1 (fr)	1981-01-30

Family

ID=22000364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR8014845A Withdrawn FR2460676A1 (fr)	1979-07-09	1980-07-03	Vaccin contre la rhinotracheite bovine infectieuse

Country Status (6)

Country	Link
CA (1)	CA1163556A (da)
DE (1)	DE3026044A1 (da)
DK (1)	DK276380A (da)
FR (1)	FR2460676A1 (da)
GB (1)	GB2052983B (da)
NL (1)	NL8003889A (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2221040C1 (ru) *	2002-06-28	2004-01-10	Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных	Штамм "вниизж" вируса инфекционного ринотрахеита крупного рогатого скота для изготовления вакцинных и диагностических препаратов
JP7432506B2 (ja)	2017-10-30	2024-02-16	武田薬品工業株式会社	脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2248054A1 (da) *	1973-10-18	1975-05-16	Flockhart & Co

1980
- 1980-06-26 DK DK276380A patent/DK276380A/da not_active Application Discontinuation
- 1980-06-30 GB GB8021393A patent/GB2052983B/en not_active Expired
- 1980-07-03 FR FR8014845A patent/FR2460676A1/fr not_active Withdrawn
- 1980-07-04 NL NL8003889A patent/NL8003889A/nl not_active Application Discontinuation
- 1980-07-08 CA CA000355701A patent/CA1163556A/en not_active Expired
- 1980-07-09 DE DE19803026044 patent/DE3026044A1/de not_active Withdrawn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2248054A1 (da) *	1973-10-18	1975-05-16	Flockhart & Co

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 92, no. 25, 23 juin 1980, page 463, résumé no. 213436h COLUMBUS OHIO (US) *

Also Published As

Publication number	Publication date
GB2052983A (en)	1981-02-04
GB2052983B (en)	1983-09-21
DE3026044A1 (de)	1981-02-05
CA1163556A (en)	1984-03-13
DK276380A (da)	1981-01-10
NL8003889A (nl)	1981-01-13

Legal Events

Date	Code	Title	Description
1985-05-24	ST	Notification of lapse

Publication	Publication Date	Title
CN1268393C (zh)	2006-08-09	经改良修饰的brsv或疫苗
Jiao et al.	2010	Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen
FR2709966A1 (fr)	1995-03-24	Vaccin pour la prévention du syndrome respiratoire et de la reproduction du porc.
MX2010014026A (es)	2011-02-15	Composiciones adyuvantes novedosas.
FR2686097A1 (fr)	1993-07-16	Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
JP2005515236A (ja)	2005-05-26	ウエストナイルワクチン
CA2699218C (en)	2019-09-10	Mycoplasma bovis vaccine
RU2420310C2 (ru)	2011-06-10	ВАКЦИНА НА ОСНОВЕ Lawsonia И СПОСОБЫ ЕЕ ПРИМЕНЕНИЯ
Neer et al.	1999	Efficacy of enrofloxacin for the treatment of experimentally induced Ehrlichia canis infection
JP2020518663A (ja)	2020-06-25	豚サーコウイルス３型免疫原性組成物、その調製方法及び用途
CA3033730A1 (en)	2018-02-22	Porcine epidemic diarrhea preventive or therapeutic method, vaccine, and vaccine kit
US4291019A (en)	1981-09-22	Vaccine for infectious bovine rhinotracheitis
Kornuta et al.	2022	TLR activation, immune response and viral protection elicited in cattle by a commercial vaccine against Bovine Herpesvirus-1
WO2011117506A2 (fr)	2011-09-29	Diluants adjuvants de vaccins vivants pour maladies porcines
CN100518739C (zh)	2009-07-29	逆转录病毒免疫疗法
AU769390B2 (en)	2004-01-22	Vaccine composition
Li et al.	2012	Co-administration of attenuated Mycoplasma hyopneumoniae 168 strain with bacterial DNA enhances the local and systemic immune response after intranasal vaccination in pigs
FR2499410A1 (fr)	1982-08-13	Vaccin contre l'avortement enzootique chez les brebis et son procede de preparation
US3000788A (en)	1961-09-19	Propagation of modified infectious canine hepatitis virus in tissue cultures of pig kidney and the preparation of a vaccine therefrom
CH382917A (fr)	1964-10-15	Procédé pour la production d'un virus-vaccin contre la maladie des chiens
JP2025516762A (ja)	2025-05-30	Ｍｏｒｉｔｅｌｌａｖｉｓｃｏｓａに対するワクチン
CA1163556A (en)	1984-03-13	Vaccine for infectious bovine rhinotracheitis
Tan et al.	1971	Further studies on feline respiratory virus diseases: 1. Vaccination experiments
FR2796282A1 (fr)	2001-01-19	Vaccin inactive contre la calicivirose feline
JPS6244528B2 (da)	1987-09-21